Business Standard

Multiple growth levers for Biocon; ramp-up, new biosimilars to boost profit

Ramp-up and new biosimilars should help boost profit

Biocon likely to channelise investments towards non-insulin biologics
Premium

Ujjval Jauhari
The Biocon stock continues to outperform its pharma peers, gaining 20 per cent since its September lows. The stock added 3 per cent to its returns on Wednesday after a decent December quarter performance, ramp-up of certain products, and fresh launches in the biologics space. The growing small molecules business, rising investments, and regulatory go-ahead for its plants are the additional triggers.

The company’s December quarter growth was led by the biologics segment, which reported a 31 per cent growth year-on-year (YoY). The segment accounts for a third of its sales. The rising sales of key biosimilars, such as Ogivri (a

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Jan 29 2020 | 11:26 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com